Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study is a local, prospective, open-label, company-sponsored, non interventional,
multi-center study. Patients documented must suffer from a cIAI and take at least one dose of
Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that
require Moxifloxacin i.v. therapy in China.
Details
Lead Sponsor:
Bayer
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination